Photo taken from: Yüksel Ürün/X
Dec 19, 2023, 18:52
Yüksel Ürün: The final analysis of the IMvigor130
Yüksel Ürün, Professor at the Department of Medical Oncology, Ankara University School of Medicine, recently posted on X/Twitter:
“The final analysis of the IMvigor130:
- Atezolizumab didn’t significantly improve overall survival compared to chemotherapy
- It may still be an effective alternative, especially for patients with high PD-L1 expression who are ineligible for cisplatin.”
For details click here.
Source: Yüksel Ürün/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14